Can Thermo Fisher Scientific execute on its massive growth opportunity, or will the doldrums of slow organic growth hold back its stock?
Eli Lilly has experienced one of the toughest patent loss challenges in the industry. Did they finally reach the bottom this quarter?
Thermo Fisher Scientific's future rests on three pillars of growth, and a big-name acquisition may tip the scales in their favor.
The laboratory equipment juggernaut showed explosive growth, but the market wasn't so impressed. Does Wall Street have this one backwards?
Eli Lilly & Co. is promising big things, but has optimism in the stock gotten ahead of reality? It's time to ask if now's the right time to invest.
Thermo Fisher Scientific is in a strong position to exploit a growing genomics market. Management knows it -- and they really want you to know it, too.
Management at Eli Lilly & Co. has faced a mountain of challenges in the wake of debilitating patent losses, but the stock has held strong regardless. Here are three reasons that rally may not continue into the future.
With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?
At a critical time for the company, Eli Lilly's management has laid out its plans to return to growth and gave us a good look at what the future holds.
The sky is the limit for wearable medical technology, but it won't be as simple as slapping a smart watch on your wrist.
Electronic health records will be a central player in the future of health care and health care reform, and they may be even more useful than you might think.
Immuno-oncology has been the darling of biotech investors, but growth in one segment of the industry might not look as strong as you think.
Patients, doctors, and investors have been excited about new frontiers in oncology, but can these drugs be useful without companion diagnostics?
With its new operating system and health app interface, Apple will enable doctors to play more of a role in patient-focused care. How will that change the landscape of health care IT providers?
What's better than a cancer treatment that binds specifically to its target? A therapy that specifically binds to two targets, of course.
The annual meeting brings together some of the world's most exciting emerging cancer treatments, and after only a day AztraZenica and Clovis are making waves as the compete in the lung cancer market.
If these three drug makers were hockey teams, you can bet they'd have what it takes to compete at hockey's highest level.
From pipelines to competitive landscapes, here are three questions that could shape a huge acquisition and the markets they operate in.
Veeva Systems overcame two major hurdles in the most recent quarter. Is it time for smooth sailing?
Can any of the number of companies struggling to cure Alzheimer's disease provide reliable investments?